Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Melanoma and Skin Cancer

Reply
 
Thread Tools Display Modes
  #1  
Old 06-02-2008, 10:09 AM
Dross Dross is offline
Moderator
 
Join Date: Nov 2006
Posts: 883
Default New combination therapy safe, promising for melanoma patients

The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago (2008).

Researchers in the melanoma and skin cancer program at UPCI combined two biotherapy treatments that stimulate the immune system to fight cancer and found the results promising in terms of anti-tumor effects and tolerable in terms of toxicity.

High-dose interferon alfa-2b, a standard treatment for metastatic skin cancer, and tremelimumab (targets oncogenic BRAF gene mutation known as V600E), an antibody thought to instigate the body's immune system to attack tumors, were combined for the first time in this phase 2 clinical trial.

With each new study, we learn something important about melanoma, said John M. Kirkwood, M.D., leader of the program and professor and vice chairman for clinical research in the Department of Medicine, University of Pittsburgh School of Medicine. With this study, we learned that adding tremelimumab to traditional treatment is not only safe, but an effective way to induce an anti-tumor response, which is very exciting.

For this study, 16 patients diagnosed with stage 4 melanoma, all of whom received and had not benefited from at least one round of previous therapy, were given the combination treatment. The overall response rate was 19 percent, and the study has since moved into the second stage, where it will enroll 21 additional patients.

Melanoma is a rare form of skin cancer, but it causes the majority of skin cancer-related deaths. Each year, approximately 160,000 new cases are diagnosed worldwide, and currently surgery is the only effective cure. For patients with inoperable disease, like those enrolled in this study, discovering a safe and effective treatment is vital.

Last edited by gdpawel : 10-29-2011 at 10:15 AM. Reason: post full article
Reply With Quote
  #2  
Old 10-29-2011, 10:23 AM
gdpawel gdpawel is offline
Moderator
 
Join Date: Feb 2007
Location: Pennsylvania
Posts: 4,354
Default New treatments to standard therapies for metastatic melanoma

Experimental treatments could be preferable to standard therapies for metastatic melanoma

By Sunni Hosemann

Introduction

Melanomas, which arise from melanocytes, are the most aggressive form of skin cancer.

Fortunately, most melanomas are discovered at an early stage when they are highly curable by surgery alone. According to data from the U.S. Surveillance, Epidemiology, and End Results program, 84% of cutaneous melanomas are discovered while localized, and for these patients, the 5-year relative survival rate is 98%.

Patients whose melanoma has spread to regional lymph nodes (stage III; about 8% of cases) have a 5-year relative survival rate of about 62%, and patients whose cutaneous melanoma is unstaged at diagnosis (about 4% of cases) have a 5-year relative survival rate of 76%. Patients who present with metastatic disease (stage IV; about 4% of cases) have a 5-year relative survival rate of only about 16%.

Types of melanoma

Although most melanomas occur on the skin surface, approximately 7% of primary melanomas are noncutaneous, according to Scott Woodman, M.D., Ph.D., an instructor in the Department of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center. Noncutaneous melanomas occur most often in the eye and mucous membranous sites such as the anus, rectum, vulva, vagina, nasal sinuses, and mouth. These tumors are associated with poorer prognoses than are cutaneous melanomas.

Noncutaneous melanomas tend to go undetected until they reach an advanced stage because they are hidden deep in the eye or in mucosa, where they cause no early symptoms. These locations also offer access to relatively rich vascular and/or lymphatic environments, enabling noncutaneous melanomas to spread more quickly than their cutaneous counterparts. Furthermore, genetic differences between cutaneous and noncutaneous melanomas cause them to have different biological behaviors and to respond differently to treatment.

According to Kevin Kim, M.D., an associate professor in the Department of Melanoma Medical Oncology, even cutaneous melanomas can differ significantly depending on where on the skin they occur and the degree of sun damage to the skin. In addition, the invasiveness of cutaneous melanomas may vary according to histological subtype; nodular melanomas are more invasive—and therefore more aggressive—than are superficial spreading, lentigo, and acral lentiginous melanomas. “Melanoma is not a single entity,” Dr. Kim said, “and this means that more tailored treatments are needed.”

Standard treatment options

“The average survival for patients with stage IV metastatic melanoma is 6–10 months,” said Michael Davies, M.D., Ph.D., an assistant professor in the Department of Melanoma Medical Oncology, “and this hasn’t changed for 30 years.”

The current standard treatment for metastatic melanoma is chemotherapy with dacarbazine, which has been shown to shrink tumors in only 10%–15% of patients who receive it. Unfortunately, this effect rarely persists more than a few months as chemoresistance develops. “In short, even though dacarbazine’s toxicity is relatively mild and the drug may prolong survival by a short time for a few patients, it’s not much better than supportive care for the majority of patients with metastatic melanoma,” Dr. Davies said.

High-dose bolus interleukin-2 (IL-2) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma in 1998. IL-2 is an immunomodulatory agent that acts by stimulating the immune system to attack the cancer cells. IL-2 has been shown to achieve rates of tumor reduction similar to those with dacarbazine, but about half the patients who respond to IL-2 have a complete response—a durable disease remission for more than 10 years. Most patients who achieve a complete response subsequently remain free of melanoma for the rest of their lives. However, according to Dr. Davies, IL-2 is among the most toxic of cancer treatments, with marked side effects and a significant risk of life-threatening adverse events. For these reasons, treatment with high-dose IL-2 requires hospitalization in a cardiac monitoring or intensive care setting at a center experienced in the agent’s administration, with cardiopulmonary specialists available. Despite these precautions and the use of IL-2 being limited to patients with excellent health and functionality, the treatment itself has a 1%–2% mortality rate.

“IL-2 is a wonderful treatment for those patients who are able to achieve a complete response and may therefore be cured of this aggressive disease,” Dr. Davies said. “Unfortunately, however, we don’t yet know how to identify those rare patients who have the best chance to benefit from this highly toxic treatment.”

Currently, IL-2 treatment can be considered only for patients who are in otherwise excellent health and only after extensive discussion of the risks and benefits of this treatment. Patients with brain metastases should be monitored with extra caution while receiving IL-2 because of the potential for edema at the tumor sites and because historical data reveal particularly low response rates to IL-2 in these patients. Interferon alfa-2b—which, like IL-2, is an immunotherapy agent—is approved by the FDA as an adjuvant treatment for patients with stage II melanoma and primary tumors more than 4-mm thick or with stage III melanoma.

Interferon alfa-2b has been shown to delay recurrence in these patients, but in most clinical studies it has not improved overall survival durations. Current studies are exploring whether interferon alfa-2b could be effective against metastatic melanoma if used in combination with chemotherapeutic agents or new immunotherapies.

Like IL-2, interferon alfa-2b involves a challenging and lengthy treatment. Interferon therapy consists of an induction phase requiring intravenous infusions five times a week for 4 weeks followed by a 48-week course of subcutaneous injections three times a week. This treatment is associated with a variety of side effects, such as flu-like symptoms, liver toxicity, and psychiatric disturbances. “With the questionable benefits of interferon therapy for improving survival in patients,” Dr. Davies said, “the side effect profile and quality of life are important considerations for patients and physicians.”
__________________
Gregory D. Pawelski
Reply With Quote
  #3  
Old 10-29-2011, 10:25 AM
gdpawel gdpawel is offline
Moderator
 
Join Date: Feb 2007
Location: Pennsylvania
Posts: 4,354
Default

Clinical trials

Because of the limited survival benefits from the FDA-approved treatments, most experts agree that clinical trials are the best option for patients with metastatic melanoma. However, even in clinical trials, progress has been slow. Not only have some promising approaches failed, but because metastatic melanoma is relatively uncommon, there have been few large, randomized trials. Nevertheless, investigators strive to develop treatment approaches that have the greatest chance of success, building upon research that has provided an improved understanding of the molecular underpinnings of melanoma.

“We want to be able to match the right patients with the right treatments,” Dr. Davies said. To make this possible, researchers at MD Anderson and other institutions have been working to identify the molecularly defined subtypes of melanoma and the ideal treatment for patients in each group.

According to Dr. Woodman, researchers have recently identified key genetic mutations in melanoma. “This is important because it provides us with the opportunity to target these tumors with specific agents,” he said.

Approximately 60% of patients with cutaneous melanomas have mutations in the BRAF gene. These mutations occur most frequently in tumors arising from skin surfaces with intermittent sun damage. Another 20% of cutaneous melanomas have NRAS mutations (which exclude BRAF). There are fewer BRAF mutations in tumors arising from non–sun-damaged areas of the skin (i.e., palms of hands, soles of feet), from chronically sun-damaged skin, and from mucosal sites. Mutations in the KIT gene are found in some of these less common melanomas, including mucosal and acral melanomas.

The identification of KIT mutations in these subtypes of melanoma has led to multiple ongoing phase II clinical trials in which melanoma patients are treated with FDA-approved agents that inhibit activated KIT in other cancers. For example, Drs. Kim and Woodman have designed a novel phase II trial to test the molecular effect of dasatinib in patients with mucosal and acral melanoma.

Other studies are under way to test experimental agents that target the mutant BRAF protein in patients with melanoma. PLX4032, an oral medication that selectively and potently inhibits the most common BRAF mutation, achieved clinical responses in more than 80% of patients with stage IV or unresectable stage III melanoma in a recent phase I clinical trial. “These results are unprecedented,” Dr. Davies said. “When you consider that the FDA-approved therapies for metastatic melanoma achieve clinical responses in only 10%–15% of patients, this trial demonstrates the dramatic potential of personalized, targeted therapies to revolutionize the treatment of this disease.” The results of the trial supported the specificity of PLX4032 for the mutant BRAF protein, as no patients who had a normal BRAF gene responded to the medication. The treatment was extremely well tolerated; a rash was the most common side effect. Phase II and III trials of PLX4032 are under way.

In early studies of another BRAF inhibitor, GSK2118436, researchers have reported similar efficacy and toxicity to that of PLX4032. While the clinical activity and limited toxicity of these targeted therapies are promising, investigators are working to improve these treatments further.

Some patients have developed new cancers of the skin as a side effect of the BRAF inhibitors. Although these tumors—which were not melanomas—were controlled with surgical removal and have not required any responding patient to discontinue BRAF inhibitor therapy, investigations are ongoing to understand why these tumors develop and how to prevent them. Another concern is that although the overwhelming majority of melanoma patients with BRAF mutations who have received BRAF inhibitors initially responded to the medication, most patients eventually develop clinical resistance to the drugs, and their tumors start growing again. “Resistance appears to develop in some patients after 7–8 months,” Dr. Davies said, “so we are looking into why that might be and considering ways to make the effects last, perhaps with combinations.”

There are a variety of combinatorial approaches being considered to combat resistance to the BRAF inhibitors, including the addition of targeted therapies against other pathways that may be activated concurrently with BRAF. Other combinations might include agents with completely different mechanisms of action, such as immunotherapy agents. Ipilimumab, a monoclonal antibody, activates T cells and has shown promise against metastatic melanoma when used alone and in combination with vaccine therapy. In a phase III trial comparing ipilimumab to the GP100 peptide vaccine in patients whose metastatic melanoma had not responded to first-line treatments, the average survival duration increased from 6 months to 10 months. “It was the first time in melanoma that an experimental drug increased survival over the control drug,” said Dr. Kim, who believes ipilimumab may have a role in future combination therapies. While ipilimumab does have the potential to cause autoimmune side effects, it does not pose the same acute cardiovascular risks as IL-2; therefore, ipilimumab can be administered safely as an outpatient treatment and potentially made available to more patients than is IL-2.

Another immune-based approach, adaptive T cell therapy, is being developed at MD Anderson under the direction of Patrick Hwu, M.D., a professor in and chair of the Department of Melanoma Medical Oncology. Dr. Kim explained that the therapy involves harvesting T cells from the patient’s tumor. The T cells are multiplied in the laboratory, and then billions of the cells are transfused back into the patient. These T cells specifically target the tumor but are not numerous or strong enough to eradicate it. To help these tumor-specific T cells proliferate in the bloodstream, patients are given chemotherapy to deplete ordinary T cells prior to the tumor-specific T cells’ reintroduction and given high-dose IL-2 to stimulate T cell growth after the T cells’ reintroduction. “Nearly 50% of patients with metastatic melanoma have had a clinical response to adaptive T cell therapy so far,” said Dr. Kim, who added that the therapy is still experimental.

These avenues of research represent important advances for patients with metastatic melanoma, for whom the current standard treatments have been woefully ineffective and/or highly toxic.

“This is a very exciting time in the history of a disease for which there have been few options,” said Dr. Woodman. “I’m optimistic that the treatment choices in 5–10 years will be very different than the ones I’ve seen thus far in my career as an oncologist.”

References

National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, Melanoma V1.2011.

Altekruse SF, Kosary CL, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975–2007. Bethesda, MD: National Cancer Institute, 2010.

Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-723.

Erratum in: N Engl J Med 2010;363(13):1290.

Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363(9):809-819.

Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24(26):4340-4346.

OncoLog, January 2011, Vol. 56, No. 1
__________________
Gregory D. Pawelski
Reply With Quote
Sponsored Links
Advertisement
  #4  
Old 06-28-2013, 11:17 PM
gdpawel gdpawel is offline
Moderator
 
Join Date: Feb 2007
Location: Pennsylvania
Posts: 4,354
Default Ipilimumab for Patients With Advanced Mucosal Melanoma

Michael A. Postow et al. perform a multicenter, retrospective analysis of 33 patients with unresectable or metastatic mucosal melanoma treated with ipilimumab. The group evaluated the activity of ipilimumab in carrying out response, overall survival, toxicity, and serologic analyses. They conclude that although the response rate is low, ipilimumab can result in durable antitumor effects in a subset of patients with mucosal melanoma.

Ipilimumab for Patients With Advanced Mucosal Melanoma

Michael A. Postow, a, Jason J. Luke, d, Mark J. Bluth, b, Nikhil Ramaiya, e, Katherine S. Panageas, c, Donald P. Lawrence, f, Nageatte Ibrahim, d, Keith T. Flaherty, f, Ryan J. Sullivan, f, Patrick A. Ott, d, Margaret K. Callahan, a, James J. Harding, a, Sandra P. D'Angelo, a, Mark A. Dickson, a, Gary K. Schwartz, a, Paul B. Chapman, a, Sacha Gnjatic, g, h, Jedd D. Wolchok, a, F. Stephen Hodi, d and Richard D. Carvajal, a

a. Departments of Medicine,
b. Radiology, and
c. Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA;
d. Department of Medical Oncology, Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA;
e. Department of Radiology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA;
f. Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA;
g. Ludwig Institute for Cancer Research, New York, New York, USA;
h. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Correspondence: Richard D. Carvajal, M.D., Melanoma-Sarcoma Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, BAIC 1071, New York, New York 10021, USA.; [email]carvajar@mskcc.org

Disclosures: Michael A. Postow: Bristol-Myers Squibb (C/A); Margaret K. Callahan: Bristol-Myers Squibb (RF); Jedd D. Wolchok: Bristol-Myers Squibb (C/A, RF); F. Stephen Hodi: Bristol-Myers Squibb (C/A, RF); Richard D. Carvajal: Bristol-Myers Squibb (RF). The other authors indicated no financial relationships.

Abstract

The outcome of patients with mucosal melanoma treated with ipilimumab is not defined. To assess the efficacy and safety of ipilimumab in this melanoma subset, we performed a multicenter, retrospective analysis of 33 patients with unresectable or metastatic mucosal melanoma treated with ipilimumab. The clinical characteristics, treatments, toxicities, radiographic assessment of disease burden by central radiology review at each site, and mutational profiles of the patients' tumors were recorded. Available peripheral blood samples were used to assess humoral immunity against a panel of cancer-testis antigens and other antigens. By the immune-related response criteria of the 30 patients who underwent radiographic assessment after ipilimumab at approximately week 12, there were 1 immune-related complete response, 1 immune-related partial response, 6 immune-related stable disease, and 22 immune-related progressive disease. By the modified World Health Organization criteria, there were 1 immune-related complete response, 1 immune-related partial response, 5 immune-related stable disease, and 23 immune-related progressive disease. Immune-related adverse events (as graded by Common Terminology Criteria for Adverse Events version 4.0) consisted of six patients with rash (four grade 1, two grade 2), three patients with diarrhea (one grade 1, two grade 3), one patient with grade 1 thyroiditis, one patient with grade 3 hepatitis, and 1 patient with grade 2 hypophysitis. The median overall survival from the time of the first dose of ipilimumab was 6.4 months (range: 1.8–26.7 months). Several patients demonstrated serologic responses to cancer-testis antigens and other antigens. Durable responses to ipilimumab were observed, but the overall response rate was low. Additional investigation is necessary to clarify the role of ipilimumab in patients with mucosal melanoma.

[url]http://theoncologist.alphamedpress.org/content/early/2013/05/22/theoncologist.2012-0464.abstract
__________________
Gregory D. Pawelski
Reply With Quote
Sponsored Links
Advertisement
Reply


Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -5. The time now is 08:40 PM.